Skip to main content

Table 4 Proportion of Clinical Response in both groups

From: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

 

P013 (N = 107)

Reference pertuzumab (N = 107)

Complete Response

64 (59.81)

61 (57.01)

Partial Response

30 (28.04)

29 (27.10)

Progressive Disease

2 (1.87)

3 (2.80)

Stable Disease

3 (2.80)

2 (1.87)

Unknown

8 (7.48)

12 (11.21)

  1. P-value = 0.99 (Fisher’s Exact test)
  2. Data are presented as No. (%)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us